Several studies have confirmed that BoNT/A1 reduces the CGRP release in migraine, its acknowledged pathophysiological mechanism, as well as the release of substance P, one of the major pain-related neuropeptides (Montecucco et al., 1996; Purkiss et al., 2000; Durham et al., 2004; Matak et al., 2017; Joussain et al., 2019). This evidence concerns the gene TAC1 and migraine disorder.